BQ-123
Phase 2Small molecule
BQ-123 is one of 148 small molecule programs targeting Pulmonary Hypertension. It is currently in Phase 2.
5
Indications
10
Total Trials
1
Active Trials
147
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
687 competitors in Heart Failure
#DrugCompanyPhaseTrials
1BQ-123
MMedical University of Vienna
Phase 2
Bayer Aspirin
BayerPreclinical
Brethine
SanofiPreclinical
Medrol
PfizerPreclinical
LCZ696
NovartisPreclinical
Activase
RochePreclinical
Zemplar
AbbViePreclinical
Savaysa
Daiichi SankyoPreclinical
Coumadin
AAbbott
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Vasoconstriction1 trial
Exercise1 trial
5 more indications
Chronic Kidney Disease1 trial
Microvascular Dysfunction1 trial
Pulmonary Hypertension1 trial
The Role of Endothelin in Pulmonary Hypertension
Completed·—·Phase 2·NCT00759408·38 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BQ-123. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMedical University of Vienna